Guest Column | By Mackenzie Ward and Jordyn Dinwiddie, Halloran Consulting Group
Large swaths of the U.S. remain healthcare deserts, where access to clinical sites, pharmacies, and hospitals is limited. This contributes to underrepresentation in clinical research. What are the roles of technology and community outreach, and what are some current industry efforts to address it?
Site payments are not easy. They are frustrating, burdensome and a drain of time and resources. A site’s inability to receive payment accurately and quickly is the result of manual, siloed processes across the entire study.
In order to have a successful clinical trial, researchers must recruit — and retain — patients. This is a struggle that researchers know well: Only one in 20 patients who respond to a recruitment promotion complete the study, with only one in five showing up for initial screening.
Guest Column | By Sonia Houston Pichardo, Yared Santa-Ana-Téllez, and Amy Rogers, IMI T@H Glossary Working Group on behalf of the Trials@Home Consortium
There is a need within the clinical trials community for a broad term to describe clinical trials that make use of digital health tech and other methods for better accessibility to participants. However, is a single term as helpful for patients as it is for clinical trial professionals?
Oncology trials placed a heavy burden on patients due to travel burden, poor patient experience, and multiyear clinical trial commitments. Sites also struggled with cancer trials due to enrollment delays, complex data workflows, and multiple amendments requiring reconsents. Today, there is a more effective, patient-first solution.
Article | By Lisa Muirhead, Nathalie Vives, Zaheda Rahman, Louis Johnson, and Crista Casey, Cmed Clinical Research Services
A patient-centric approach results in trial participants who are more likely to both consent for and complete a clinical study. Read more about recent changes in industry requirements and some of the important patient-centric techniques and strategies that are gaining visibility across the industry.
Clinical trials are becoming increasingly decentralized, and Q² Solutions is committed to discovering innovative ways of improving the patient and investigator experience.
Guest Column | By Anna DeSalvo, MS, CGC, National Marrow Donor Program/Be The Match
It is no secret that people who are ethnically diverse are underrepresented in clinical trials, and that is a trend that needs to change. But how? Discover six ways you can increase trial diversity starting now.
Managing clinical trials requires extensive planning of patient enrollment. Clinical trials may be more cost-effective with better forecasts of recruitment.
In this expert advice round-up, Jonathan Andrus, president and COO at CRIO, discusses the future of diversity-driven clinical trials (DDCs) and the global regulations shaping the industry.
Explore why the under-representation of racial and ethnic minorities in clinical trials in the United States is too staggering to ignore.
Choose Your Own Adventure
You're receiving the Monday edition of the Clinical Leader newsletter, focusing on Clinical Sites, Patient Centricity, and Patient Recruitment. To make changes to your newsletter selections, update your topic preferences.
Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here.
This newsletter is being sent to {{lead.Email Address}}. If the topics covered in it are no longer of interest to you, you can change your topic preferences on your profile page. To cancel your subscription to all Clinical Leader newsletters, please unsubscribe.
This website uses cookies to ensure you get the best experience on our website. Learn more